Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Combinations in Advanced Gastric or GEJ Adenocarcinoma
NCT05702229Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2023
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of volrustomig, rilvegostomig, sonesitatug vedotin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by AstraZeneca. Started Jan 2023; status: recruiting.
02
Drugs
volrustomigrilvegostomigsonesitatug vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05702229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05702229.